Pharmacorp Rx arranges $15-million financing

Executive Summary

• Pharmacorp Rx Inc. has entered into an agreement for a C$15 million bought deal public offering of 35.7 million units.
• The offering is co-led by underwriters Canaccord Genuity Corp. and Acumen Capital Finance Partners Ltd.
• Net proceeds will be utilized for future acquisition opportunities and general working capital requirements.

Key Details

• Transaction Structure: Bought deal public offering.
• Underwriters: Syndicate co-led by Canaccord Genuity Corp. and Acumen Capital Finance Partners Ltd.
• Units Sold: 35.7 million units.
• Price: 42 cents per unit.
• Gross Proceeds: $15.0 million.
• Unit Composition: Each unit consists of one common share and one-half of one common share purchase warrant.
• Warrant Terms: Each whole warrant entitles the holder to acquire one common share at an exercise price of 50 cents.
• Warrant Expiry: 24 months from the closing date.
• Use of Proceeds: Future acquisition opportunities and general working capital requirements.
• Closing Date: Expected on or about November 12, 2025, subject to regulatory approvals (including TSX Venture Exchange) and formal documentation.
• Overallotment Option: Underwriters have an option to purchase up to 15% additional units/shares/warrants (approx. 5.355 million units) within 30 days of closing for overallotment and market stabilization.
• Regulatory Filing: Offered via prospectus supplement to the Short Form Base Shelf Prospectus dated October 14, 2025.

Notable Quotes

• None provided in the text.